CH681060A5 - - Google Patents
Download PDFInfo
- Publication number
- CH681060A5 CH681060A5 CH2728/90A CH272890A CH681060A5 CH 681060 A5 CH681060 A5 CH 681060A5 CH 2728/90 A CH2728/90 A CH 2728/90A CH 272890 A CH272890 A CH 272890A CH 681060 A5 CH681060 A5 CH 681060A5
- Authority
- CH
- Switzerland
- Prior art keywords
- sep
- sobrerol
- trans
- head col
- title
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- OMDMTHRBGUBUCO-BDAKNGLRSA-N (1s,5r)-5-(2-hydroxypropan-2-yl)-2-methylcyclohex-2-en-1-ol Chemical compound CC1=CC[C@@H](C(C)(C)O)C[C@@H]1O OMDMTHRBGUBUCO-BDAKNGLRSA-N 0.000 claims description 17
- 230000000510 mucolytic effect Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000954 anitussive effect Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 description 6
- OMDMTHRBGUBUCO-IUCAKERBSA-N (1s,5s)-5-(2-hydroxypropan-2-yl)-2-methylcyclohex-2-en-1-ol Chemical compound CC1=CC[C@H](C(C)(C)O)C[C@@H]1O OMDMTHRBGUBUCO-IUCAKERBSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 235000007173 Abies balsamea Nutrition 0.000 description 2
- 239000004857 Balsam Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000018716 Impatiens biflora Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960000230 sobrerol Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- OMDMTHRBGUBUCO-UHFFFAOYSA-N trans-sobrerol Natural products CC1=CCC(C(C)(C)O)CC1O OMDMTHRBGUBUCO-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 208000027775 Bronchopulmonary disease Diseases 0.000 description 1
- 241000252095 Congridae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH2728/90A CH681060A5 (cs) | 1990-08-22 | 1990-08-22 | |
| EP91914459A EP0496858A1 (en) | 1990-08-22 | 1991-08-12 | Pharmaceutical compositions with mucolytic and antitussive activity containing (-)-trans-sobrerol |
| PCT/EP1991/001530 WO1992003128A1 (en) | 1990-08-22 | 1991-08-12 | Pharmaceutical compositions with mucolytic and antitussive activity containing (-)-trans-sobrerol |
| AU83274/91A AU8327491A (en) | 1990-08-22 | 1991-08-12 | Pharmaceutical compositions with mucolytic and antitussive activity containing (-)-trans-sobrerol |
| JP3513874A JPH05502892A (ja) | 1990-08-22 | 1991-08-12 | （−）―トランス―ソブレロールを含有する粘液溶解活性及び鎮咳活性をもつ医薬組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH2728/90A CH681060A5 (cs) | 1990-08-22 | 1990-08-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH681060A5 true CH681060A5 (cs) | 1993-01-15 |
Family
ID=4240272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH2728/90A CH681060A5 (cs) | 1990-08-22 | 1990-08-22 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0496858A1 (cs) |
| JP (1) | JPH05502892A (cs) |
| AU (1) | AU8327491A (cs) |
| CH (1) | CH681060A5 (cs) |
| WO (1) | WO1992003128A1 (cs) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030047503A (ko) * | 2001-12-11 | 2003-06-18 | 진양제약주식회사 | 소브레롤·아세트아미노펜 복합 건조시럽제 및 액제 |
| CN102911890B (zh) * | 2011-08-05 | 2014-06-04 | 烟台海上传奇生物科技有限公司 | 可代谢己烯雌酚的假单胞菌及其应用 |
| CN108601755B (zh) * | 2015-09-09 | 2021-08-10 | 韩国生命工学研究院 | 用于预防或治疗肌无力相关疾病的、包含水合蒎醇的组合物 |
| TWI779059B (zh) * | 2017-06-30 | 2022-10-01 | 財團法人工業技術研究院 | 化合物用於製備治療自體免疫神經疾病及/或神經退化性疾病之藥物的用途 |
| KR102804780B1 (ko) * | 2024-01-17 | 2025-05-15 | 주식회사 뉴롤메드 | 인지기능 장애의 치료용 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH568951A5 (cs) * | 1970-04-17 | 1975-11-14 | Corvi Camillo Spa | |
| IT1180220B (it) * | 1984-08-08 | 1987-09-23 | Corvi Camillo Spa | Miscela di composti diastereoisomeri, ottenuti da (-)-5-(1-idrossi-1-metiletil)-2-metil-2-cicloesen-1-one, avente attivita' mucosecretolitica, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono |
| DD262874A1 (de) * | 1987-07-31 | 1988-12-14 | Akad Wissenschaften Ddr | Verfahren zur mikrobiellen transformation von alpha-pinenen zu verbenolen |
-
1990
- 1990-08-22 CH CH2728/90A patent/CH681060A5/de not_active IP Right Cessation
-
1991
- 1991-08-12 WO PCT/EP1991/001530 patent/WO1992003128A1/en not_active Ceased
- 1991-08-12 EP EP91914459A patent/EP0496858A1/en not_active Withdrawn
- 1991-08-12 AU AU83274/91A patent/AU8327491A/en not_active Abandoned
- 1991-08-12 JP JP3513874A patent/JPH05502892A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU8327491A (en) | 1992-03-17 |
| JPH05502892A (ja) | 1993-05-20 |
| EP0496858A1 (en) | 1992-08-05 |
| WO1992003128A1 (en) | 1992-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2817358C2 (cs) | ||
| DE3514054C2 (cs) | ||
| DD202001A5 (de) | Verfahren zur herstellung von aminoaethanolen | |
| DE69104314T2 (de) | Verwendung von 1-[3-(Dimethylamino)propyl]-1-phenylphthalenen zur Behandlung zerebrovaskulärer Störungen. | |
| EP0607775A2 (de) | Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta | |
| DE4241013A1 (de) | Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung | |
| DE3744947C2 (cs) | ||
| DE3347867C2 (cs) | ||
| DE69829202T2 (de) | Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen | |
| CH681060A5 (cs) | ||
| DE69129750T2 (de) | Neue medizinische anwendung eines gewissen indolderivates und dieses enthaltende pharmazeutische zubereitung | |
| AT397097B (de) | Neue alkoxyderivate der ginkgolide, ihre herstellung und sie enthaltende therapeutische zusammensetzungen | |
| DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
| DE60216776T2 (de) | Neue piperidin-2,6-dion bisulfatsalze und deren verwendung für die behandlung stressbezogener gemütserkrankungen | |
| DE2362123A1 (de) | Pharmazeutische zubereitungen | |
| US3097136A (en) | Process for producing a depressant-like effect on the central nervous system | |
| US4816481A (en) | Method for improving cerebral circulation | |
| DE60306396T2 (de) | Piperidin-2,6-Dionpamoat-Salze und ihre Verwendung zur Behandlung von stressbedingten affektiven Störungen | |
| DE2632118A1 (de) | Apovincaminolester und verfahren zu deren herstellung | |
| DE1940566A1 (de) | 1-(2-Nitrilophenoxy)-2-hydroxy-3-aethylaminopropan und dessen Salze | |
| CH675125A5 (cs) | ||
| DE2244737C3 (de) | H-o-Chlorphenyl)-2-tert-butylaminoäthanol, Verfahren zu dessen Herstellung und Arzneimittel auf dessen Basis | |
| DE3136455C2 (de) | Verwendung von Caerulein oder dessen pharmazeutisch verträglichen Salzen bei der Bekämpfung von psychotischen Krankheitszuständen | |
| CH556323A (de) | Verfahren zur herstellung von neuen naphthylalkylaminen. | |
| DE3511236C2 (cs) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |